Holista CollTech Ltd
Holista CollTech Ltd is a biotechnology company focused on the development and commercialization of collagen-based products for healthcare diagnostics and other applications.
Business. Holista CollTech Ltd (HCT.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Holista CollTech Ltd (HCT.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Holista CollTech operates with a capital structure that includes 367,834,364 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. The company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, suggesting a lack of transparency in its short-term financial health.
The company reported a revenue of 38,000 AUD and an EPS of -0.10 AUD, indicating a loss per share and a very low revenue base. These figures suggest that the company is not yet profitable and is likely in an early-stage or development phase, which is common in the biotechnology and medical research industry.
Holista CollTech's revenue is not segmented by geographic region or business segment in the available data, making it difficult to assess the geographic or product concentration of its revenue. This lack of segmentation could pose a risk if the company is overly reliant on a single market or product line.
The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The absence of detailed growth metrics makes it challenging to assess the company's potential for future expansion or profitability.
The risk assessment indicates a low dilution risk, but the company's liquidity risk could not be evaluated due to insufficient financial data. This lack of information may hinder investors' ability to fully understand the company's financial stability and operational risks.
There are no recent events or filings mentioned in the available data that would provide insight into the company's current operations or strategic direction. The absence of recent disclosures or transcripts suggests a lack of public communication or transparency from the company.
- Holista CollTech is a biotechnology company with a focus on collagen-based products for healthcare diagnostics.
- The company reported a revenue of 38,000 AUD and an EPS of -0.10 AUD, indicating a loss per share and a very low revenue base.
- The company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- There is no segmentation of revenue by geographic region or business segment, making it difficult to assess the geographic or product concentration of its revenue.
- The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided.
- The risk assessment indicates a low dilution risk, but the company's liquidity risk could not be evaluated due to insufficient financial data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue A$5.8M, +3,3% YoY; Operating income −365,1% YoY.
- ▍Revenue A$5.8M, +3,3% YoY
- ▍Operating income −365,1% YoY
- ▍Net income −1 026,8% YoY
- ▍Free cash flow −24 303,7% YoY
- ▍Net margin -16.4%
Revenue A$5.6M, −5,8% YoY; Operating income +106,3% YoY.
- ▍Revenue A$5.6M, −5,8% YoY
- ▍Operating income +106,3% YoY
- ▍Net income +98,2% YoY
- ▍Free cash flow +99,9% YoY
- ▍Net margin -1.5%
Revenue A$8.2M, +2,6% YoY; Operating income −19,9% YoY.
- ▍Revenue A$8.2M, +2,6% YoY
- ▍Operating income −19,9% YoY
- ▍Net income −15,7% YoY
- ▍Free cash flow −9,3% YoY
- ▍Net margin -17.6%
Revenue A$5.9M, −27,8% YoY; Operating income −255,6% YoY.
- ▍Revenue A$5.9M, −27,8% YoY
- ▍Operating income −255,6% YoY
- ▍Net income −230,8% YoY
- ▍Free cash flow −259,2% YoY
- ▍Net margin -80.8%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Holista CollTech Ltd Market data — financials · 2026-05-28
- Holista CollTech Ltd Market data — analyst estimates · 2026-05-28